Blood test tracks Parkinson progression
- Trial ID
- NCT06941012
- Official Title
- Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution (VaMPiRE)
- Goal
- Blood test tracks Parkinson progression
- Status
- RECRUITING
- Sponsor
- Casa di Cura IGEA
- Study Type
- OBSERVATIONAL
- Enrollment
- 1200 participants
- Conditions
- Parkinson Disease (PD)
- Interventions
- Blood draw for the laboratory assessment
Plain-Language Summary
VaMPiRE aims to find whether specific chemical modifications of the α-synuclein protein in blood track Parkinson's progression or can help tell people with PD apart from those without. The team will collect blood samples to measure modified forms of α-synuclein, the protein that misfolds and clumps in Parkinson's, looking for patterns linked to symptom severity or disease stage; this is observational only and does not change medications or interact with levodopa. Adults 18 to 85 are eligible, including people with PD diagnosed by MDS-UPDRS and Hoehn and Yahr stages I,IV while on meds, plus neurologically normal controls, with exclusions for severe cognitive decline, active infections, other confounding neurological conditions, or life‑threatening illnesses.
Locations
- Aristotle University of Thessaloniki, Thessaloniki, Greece
- Casa di Cura Igea, Milan, Mi, Italy
- Instytut Psychiatrii I Neurologii, Warsaw, Poland
- Asociacion Parkinson Madrid, Madrid, Spain
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Blood draw for the laboratory assessment. VaMPiRE aims to find whether specific chemical modifications of the α-synuclein protein in blood track Parkinson's progression or can help tell people with PD apart from those without. The team will collect blood samples to measure modified forms of α-synuclein, the protein that misfolds and clumps in Parkinson's, looking for patterns linked to symptom severity or disease stage; this is observational only and does not change medications or interact with levodopa. Adults 18 to 85 are eligible, including people with PD diagnosed by MDS-UPDRS and Hoehn and Yahr stages I,IV while on meds, plus neurologically normal controls, with exclusions for severe cognitive decline, active infections, other confounding neurological conditions, or life‑threatening illnesses.
- Who can participate?
- Participants must be between 18 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 4 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 7 months.